Figure 4From: Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout Mean serum pegloticase concentrations in responders and nonresponders receiving pegloticase biweekly (top panel) or monthly (bottom panel). Back to article page